Comparison · NCT02977507-sae
Left Side Lytera 2.0, Right Side 4% Hydroquinone vs Left Side 4% Hydroquinone, Right Side Lytera 2.0: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Left Side Lytera 2.0, Right Side 4% Hydroquinone vs Left Side 4% Hydroquinone, Right Side Lytera 2.0: serious adverse events. Trial comparisons, record NCT02977507-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02977507-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.125 | 0.0224 | 0.471 | wilson | |
| Risk in group 2 | 0 | 0 | 0.278 | wilson | |
| Risk difference, group 1 minus group 2 | 0.125 | -0.171 | 0.471 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | log | a group has no participants with the outcome | |||
| Odds ratio, group 1 over group 2 | log | a cell of the two-by-two table is zero | |||
| Number needed to harm, for one more participant with a serious adverse event on Left Side Lytera 2.0, Right Side 4% Hydroquinone than on Left Side 4% Hydroquinone, Right Side Lytera 2.0 | 8 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Left Side Lytera 2.0, Right Side 4% Hydroquinone | Lytera 2.0 applied to the affected areas (dark patches) on the left side of the face and 4% hydroquinone topical prescription cream applied to the affected areas on the right side of the face twice a day, in the morning and evening, every day for 12 weeks. SkinMedica Facial Cleanser, SkinMedica Rejuvenative Moisturizer, and SkinMedica Essential Defense Mineral Shield Broad Spectrum SPF 35 Sunscreen were also applied to the face as directed. | 1 | 8 | EG000 |
| Group 2 | Left Side 4% Hydroquinone, Right Side Lytera 2.0 | 4% hydroquinone topical prescription cream applied to the affected areas (dark patches) on the left side of the face and Lytera 2.0 applied to the affected areas on the right side of the face twice a day, in the morning and evening, every day for 12 weeks. SkinMedica Facial Cleanser, SkinMedica Rejuvenative Moisturizer, and SkinMedica Essential Defense Mineral Shield Broad Spectrum SPF 35 Sunscreen were also applied to the face as directed. | 0 | 10 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- From first dose of study drug up to 12 weeks
Source ClinicalTrials.gov
Trial
- Title
- Split-face Study Comparing the Cosmetic Efficacy and Tolerability of Two Topical Products in Participants With Moderate Facial Melasma
- NCT number
- NCT02977507
- Phases
- NA
- Conditions
- Melasma
- Interventions
- Lytera 2.0, 4% Hydroquinone Topical Cream, SkinMedica Facial Cleanser, SkinMedica Rejuvenative Moisturizer, SkinMedica Essential Defense Mineral Shield Broad Spectrum SPF 35 Sunscreen
- Lead sponsor
- Allergan
- Results first posted
- 2018-11-07
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02977507?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02977507-sae